Home Cart Sign in  
Chemical Structure| 568-80-9 Chemical Structure| 568-80-9

Structure of Galloflavin
CAS No.: 568-80-9

Chemical Structure| 568-80-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Galloflavin is an inhibitor of both LDH-A and -B with Ki values of 5.46 μM (LDH-A) and 15.06 μM (LDH-B), respectively. It inhibits both human LDH isoforms by preferentially binding the free enzyme, without competing with the substrate or cofactor.

Synonyms: NSC 107022

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Galloflavin

CAS No. :568-80-9
Formula : C12H6O8
M.W : 278.17
SMILES Code : O=C(O1)C(O)=CC(OC2=O)=C1C3=C2C=C(O)C(O)=C3O
Synonyms :
NSC 107022
MDL No. :MFCD26941292
InChI Key :UXHISTVMLJLECY-UHFFFAOYSA-N
Pubchem ID :135483971

Safety of Galloflavin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical cord-derived MSCs (UC-MSCs) 50 µM 24 hours Inhibition of LDHA activity, reducing lactate production, thereby decreasing the immunosuppressive capacity of UC-MSCs on CD4+ and CD8+ T cells Stem Cell Res Ther. 2023 Nov 19;14(1):335
Murine CD4+ T cells 50 µM 24 hours Inhibition of LDHA activity, reducing lactate production, thereby decreasing the immunosuppressive capacity of MSCs on Th1 and Th17 cells Stem Cell Res Ther. 2023 Nov 19;14(1):335
Primary cultures of endometrial cancer cells 20-53 uM 72 hours To evaluate the effect of GF on primary endometrial cancer cell growth, results showed GF effectively inhibited cell proliferation in 6/8 primary cultures. J Hematol Oncol. 2015 Jan 29;8:2
Ishikawa cells 43 uM 72 hours To evaluate the effect of GF on endometrial cancer cell growth, results showed GF significantly inhibited cell proliferation and reduced colony formation. J Hematol Oncol. 2015 Jan 29;8:2
ECC-1 cells 25 uM 72 hours To evaluate the effect of GF on endometrial cancer cell growth, results showed GF significantly inhibited cell proliferation and reduced colony formation. J Hematol Oncol. 2015 Jan 29;8:2
human colon adenocarcinoma cells (Caco2) 0-100 μM 6-24 hours To investigate the effects of Galloflavin on SIRT6 expression and glycolytic proteins. Results showed that Galloflavin significantly upregulated SIRT6 expression by 3.5-fold at 25-50 μM concentrations and decreased GLUT1 expression and glucose uptake. Biomed Pharmacother. 2020 Nov;131:110701
SW480 cells 5 and 15 μM 6 hours Galloflavin treatment could significantly attenuate the malignant behavior of SW480 in the inflammatory microenvironment and inhibit the migration and invasion capabilities of SW480. Front Pharmacol. 2021 Dec 10;12:752118

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Delayed type 1 hypersensitivity (DTH) model 50 µM Single dose, lasting 24 hours Inhibition of LDHA activity, reducing lactate production, thereby decreasing the anti-inflammatory capacity of MSCs in the DTH model Stem Cell Res Ther. 2023 Nov 19;14(1):335
Balb/c nude mice Tumor-bearing mice model Intragastric administration 5 and 15 mg/kg Once daily for 15 days Galloflavin could inhibit tumor growth and decrease the expression of NLRP in tumor-bearing mice. Front Pharmacol. 2021 Dec 10;12:752118

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.59mL

0.72mL

0.36mL

17.97mL

3.59mL

1.80mL

35.95mL

7.19mL

3.59mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories